Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;40(1):44-55.
doi: 10.1053/j.semperi.2015.11.007. Epub 2015 Dec 21.

Pre- and post-test genetic counseling for chromosomal and Mendelian disorders

Affiliations
Review

Pre- and post-test genetic counseling for chromosomal and Mendelian disorders

Jill Fonda Allen et al. Semin Perinatol. 2016 Feb.

Abstract

Genetic carrier screening, prenatal screening for aneuploidy, and prenatal diagnostic testing have expanded dramatically over the past 2 decades. Driven in part by powerful market forces, new complex testing modalities have become available after limited clinical research. The responsibility for offering these tests lies primarily on the obstetrical care provider and has become more burdensome as the number of testing options expands. Genetic testing in pregnancy is optional, and decisions about undergoing tests, as well as follow-up testing, should be informed and based on individual patients' values and needs. Careful pre- and post-test counseling is central to supporting informed decision-making. This article explores three areas of technical expansion in genetic testing: expanded carrier screening, non-invasive prenatal screening for fetal aneuploidies using cell-free DNA, and diagnostic testing using fetal chromosomal microarray testing, and provides insights aimed at enabling the obstetrical practitioner to better support patients considering these tests.

Keywords: Cell-free DNA screening; Chromosome microarray; Genetic carrier screening; Genetic counseling; Non-invasive prenatal screening; Prenatal diagnosis.

PubMed Disclaimer

References

    1. de Jong A, Dondorp WJ, Macville MV, de Die-Smulders CE, van Lith JM, de Wert GM. Microarrays as a diagnostic tool in prenatal screening strategies: ethical reflection. Hum Genet. 2014;133(2):163–172. - PubMed
    1. Bernhardt BA, Soucier D, Hanson K, Savage MS, Jackson L, Wapner RJ. Women’s experiences receiving abnormal prenatal chromosomal microarray testing results. Genet Med. 2012;15(2):139–145. - PMC - PubMed
    1. Kalfoglou AL, Doksum T, Bernhardt B, et al. Opinions about new reproductive genetic technologies: hopes and fears for our genetic future. Fertility and Sterility. 2005;83(6):1612–1621. - PubMed
    1. Hui L. Non-invasive prenatal testing for fetal aneuploidy: charting the course from clinical validity to clinical utility. Ultrasound Obstet Gynecol. 2013;41(1):2–6. doi: 10.1002/uog.12360. - DOI - PubMed
    1. Allyse M, Chandrasekharan S. Too much, too soon?: Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond. Genet Med. 2015 Mar 19; doi: 10.1038/gim.2015.23. - DOI - PMC - PubMed

Publication types